Incyte Corp Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

A sample of Incyte Corp Insights data

Headline Published Journalists
Showing 3 of 90+ results. Subscribe to unlock more.
Deserunt mollit sunt Lorem laborum do id aliqua dolore 24 Jun 2022 Lorem
LoA Update: Incyte’s advanced malignancies candidate plunges in regulatory chances after Phase I/II terminates 15 Dec 2021 William Newton
JAK inhibitors still have valuable uptake opportunities in moderate-to-severe atopic dermatitis despite threat of black box warning 23 Sep 2021 Reynald Castaneda
LoA Update: Incyte’s potential for its Phase II asset for kidney cancer to move to the next developmental stage plummets to 22% 22 Jul 2021 Humeza Ahmed
Insights

Feature

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Benefit

Drug Insights:

  • Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
  • Material intelligence on competitors, including breaking news
  • Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Value

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Premium databases is part of our industry range of products

Subscribe to Company Analytics & gain 12-month access to premium industry data & analytics
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer